Tae Woo Park1,2, Debbie M Cheng3,4, Christine A Lloyd-Travaglini5, Judith Bernstein6, Tibor P Palfai7, Richard Saitz6,4. 1. Division of General Internal Medicine, Department of Medicine, Alpert Medical School and Rhode Island Hospital, Providence, RI, USA. 2. Department of Psychiatry and Human Behavior, Alpert Medical School and Rhode Island Hospital, Providence, RI, USA. 3. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 4. Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA. 5. Data Coordinating Center, Boston University School of Public Health, Boston, MA, USA. 6. Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA. 7. Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA.
Abstract
AIMS: To test (1) whether abstinence and reduction in illicit psychoactive drug use were associated with changes in health outcomes in primary care patients and (2) whether these associations varied by drug type. DESIGN: Secondary analysis of data from a randomized controlled trial that tested a brief intervention for drug use in primary care patients (589 enrolled, 574 completed a 6-month assessment). Analyses were conducted overall and stratified by the most commonly self-identified main drugs (marijuana, cocaine and opioids). SETTING AND PARTICIPANTS: Patients who screened positive for illicit drug use at an urban primary care clinic in Boston, Massachusetts, USA. MEASUREMENTS: Differences in past-month main drug use at baseline and 6-month outcome were categorized as continued or increased use, decreased use without abstinence and abstinence. Primary outcomes were 6-month changes in drug use consequences [Short Inventory of Problems scores (range 0-45)], depressive symptoms and health-related quality of life (HRQol). FINDINGS: Abstinence was associated with a greater decrease in adverse drug use consequences than continued or increased use among the full sample and cocaine and opioids subgroups (adjusted means, full sample: -8.11 versus -0.05, P < 0.001; cocaine: -13.33 versus +1.09, P < 0.001, opioids; -16.84 versus -2.10, P < 0.001). Differences were not significant between those who decreased use compared with those who continued or increased use. There were no significant associations between drug use and depressive symptoms or HRQol. Neither abstinence nor decreased use was associated significantly with consequences in the marijuana subgroup. CONCLUSIONS: Among primary care patients in the United States who use illicit psychoactive drugs, abstinence but not reduction in use without abstinence appears to be associated with decreased adverse drug use consequences.
RCT Entities:
AIMS: To test (1) whether abstinence and reduction in illicit psychoactive drug use were associated with changes in health outcomes in primary care patients and (2) whether these associations varied by drug type. DESIGN: Secondary analysis of data from a randomized controlled trial that tested a brief intervention for drug use in primary care patients (589 enrolled, 574 completed a 6-month assessment). Analyses were conducted overall and stratified by the most commonly self-identified main drugs (marijuana, cocaine and opioids). SETTING AND PARTICIPANTS: Patients who screened positive for illicit drug use at an urban primary care clinic in Boston, Massachusetts, USA. MEASUREMENTS: Differences in past-month main drug use at baseline and 6-month outcome were categorized as continued or increased use, decreased use without abstinence and abstinence. Primary outcomes were 6-month changes in drug use consequences [Short Inventory of Problems scores (range 0-45)], depressive symptoms and health-related quality of life (HRQol). FINDINGS: Abstinence was associated with a greater decrease in adverse drug use consequences than continued or increased use among the full sample and cocaine and opioids subgroups (adjusted means, full sample: -8.11 versus -0.05, P < 0.001; cocaine: -13.33 versus +1.09, P < 0.001, opioids; -16.84 versus -2.10, P < 0.001). Differences were not significant between those who decreased use compared with those who continued or increased use. There were no significant associations between drug use and depressive symptoms or HRQol. Neither abstinence nor decreased use was associated significantly with consequences in the marijuana subgroup. CONCLUSIONS: Among primary care patients in the United States who use illicit psychoactive drugs, abstinence but not reduction in use without abstinence appears to be associated with decreased adverse drug use consequences.
Authors: Richard Saitz; Tibor P A Palfai; Debbie M Cheng; Daniel P Alford; Judith A Bernstein; Christine A Lloyd-Travaglini; Seville M Meli; Christine E Chaisson; Jeffrey H Samet Journal: JAMA Date: 2014-08-06 Impact factor: 56.272
Authors: Peter Roy-Byrne; Kristin Bumgardner; Antoinette Krupski; Chris Dunn; Richard Ries; Dennis Donovan; Imara I West; Charles Maynard; David C Atkins; Meredith C Graves; Jutta M Joesch; Gary A Zarkin Journal: JAMA Date: 2014-08-06 Impact factor: 56.272
Authors: Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate Journal: Drug Alcohol Depend Date: 2019-09-04 Impact factor: 4.492
Authors: Nitika Sanger; Meha Bhatt; Laura Zielinski; Stephanie Sanger; Hamnah Shahid; Bianca Bantoto; M Constantine Samaan; Russell de Souza; Zainab Samaan Journal: Syst Rev Date: 2018-01-25